Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) announced its quarterly earnings results on Thursday. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.09), MarketWatch Earnings reports.

Shares of DAWN traded up $0.70 during mid-day trading on Friday, hitting $7.65. 461,834 shares of the company’s stock were exchanged, compared to its average volume of 218,898. Day One Biopharmaceuticals has a fifty-two week low of $6.53 and a fifty-two week high of $28.70. The stock’s 50-day moving average is $10.14 and its 200-day moving average is $14.62.

Several institutional investors and hedge funds have recently modified their holdings of the company. Morgan Stanley lifted its position in shares of Day One Biopharmaceuticals by 25.0% during the third quarter. Morgan Stanley now owns 2,967 shares of the company’s stock worth $70,000 after purchasing an additional 593 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Day One Biopharmaceuticals by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 76,168 shares of the company’s stock worth $1,284,000 after buying an additional 942 shares during the period. Royal Bank of Canada purchased a new position in Day One Biopharmaceuticals in the third quarter valued at approximately $33,000. Citigroup Inc. increased its stake in Day One Biopharmaceuticals by 266.1% in the fourth quarter. Citigroup Inc. now owns 4,682 shares of the company’s stock valued at $79,000 after purchasing an additional 3,403 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Day One Biopharmaceuticals by 1,074.6% in the fourth quarter. Bank of America Corp DE now owns 5,685 shares of the company’s stock valued at $96,000 after acquiring an additional 5,201 shares during the period. 79.02% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research raised shares of Day One Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $34.25.

About Day One Biopharmaceuticals (Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Stories

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.